Decreased the responsiveness of blood vessels to vasodilator and vasoconstrictor drugs in animals led to its investigation in the prevention of migraine in man. Results of placebo-controlled and open therapeutic trialshave shown that clonidine in low dosages (75 to 150μg daily) isuseful in preventing migraine headaches in about 30 to 50% of patients. A 50% or greater reduction in headache frequency or headache indices has been reported in 40% of patients in controlled and open studies. Thus clonidine, like other drugs used in the interval therapy of migraine, can be expected to be effective in only a proportion of patients. Although clonidine has not been compared directly with other drugs used in the prophylactic treatment of migraine, the general clinical impression is that it is less effective then pizotifen or methysergide. Because it is relatively well tolerated at dosages of 75 to 150/ug daily it is worthy of a trial, particularly in patients considered to need prophylactic migraine therapy for the first time, and when migraine occurs in association with hypertension. At the dosages used in migraine prophylaxis, which are almost invariably lower than used in hypertension, clonidine does not cause hypotension and can be used in patients with cardiovascular disease. Dixarit tablets contain the active ingredient clonidine, which is a medicine used in the prevention of migraine headaches. Clonidine is also available without a brand name, ie as the generic medicine. Although the cause of migraine attacks is not fully understood, it is thought that the widening of blood vessels in the brain causes the pain associated with migraine attacks. Dixarit tablets are used to prevent migraines and to treat menopausal flushing, though it is not fully understood how it works in these conditions. Clonidine is thought to reduce the responsiveness of small blood vessels to stimuli which would normally make them contract (narrow) or dilate (widen). This prevents the changes in the blood vessels of the brain which are associated with migraine, and thus prevents attacks. It also prevents the dilatation of blood vessels and subsequent increased blood flow to the skin, which causes hot flushes in menopausal women.
Catapres is the tradename for an alpha agonist, antihypertensive drug generically known as clonidine. This medication is sometimes confused with the anti-anxiety medication Klonopin. European studies have shown it effective in the prevention of migraines, especially in food-sensitive migraines. It can also help reduce symptoms for patients withdrawing from narcotics. Unlike beta blockers, it can be used by patients with diabetes mellitus and asthma or other respiratory disorders The combined use of clonidine with tricyclic antidepressants may render clonidine ineffective. Side effects include low blood pressure and dizziness. Catapres is available in oral tablets or a patch applied to the skin. Wall, MD, MPH; Christel Mottur-Pilson, Ph D; American Academy of Family Physicians and the American College of Physicians–American Society of Internal Medicine* *This paper, written by Vincenza Snow, MD, Kevin Weiss, MD, Eric M. Yawn, MD, MSc; Geoffrey Goldsmith, MD, MPH; Richard D. Note: Clinical practice guidelines are “guides” only and may not apply to all patients and all clinical situations. Wall, MD, MPH, and Christel Mottur-Pilson, Ph D, was developed by the Commission on Clinical Policies and Research of the American Academy of Family Physicians (AAFP) and by the Clinical Efficacy Assessment Subcommittee of the American College of Physicians–American Society of Internal Medicine (ACP–ASIM). Thus, they are not intended to override clinicians' judgment. Commission on Clinical Policies and Research: Theodore G. All ACP–ASIM clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication or once an update has been issued. Approved by the ACP–ASIM Board of Regents on 26 March 2001 and by the AAFP Board of Directors on 8 August 2001. Kabongo, MD, Ph D; Robert Bonakdar, MD; and Michael A. Clinical Efficacy Assessment Subcommittee: David Dale, MD (); Patricia Barry, MD; William Golden, MD; Robert Mc Cartney, MD; Keith Michl, MD; Allan Ronald, MD; Sean Tunis, MD; and Preston Winters, MD. Acknowledgments: The authors thank David Matchar, MD, for his long-standing dedication and commitment to this project, both as ACP–ASIM representative to the U. Headache Consortium and as the architect of the collaboration that led to the writing of these guidelines. Requests for Single Reprints: Vincenza Snow, MD, American College of Physicians–American Society of Internal Medicine, 190 N. Headache Consortium was to develop scientifically sound, clinically relevant practice guidelines on chronic headache, particularly migraine, in the primary care setting.
Nov 15, 2012. The demonstration that long-term administration of relatively low doses of clonidine 2decreased the responsiveness of blood vessels to. Evidence-Based Guidelines for Migraine Headache in the Primary Care. prevention of migraine 16 of clonidine,19-34 and one of guanfacine.30 The evidence.